Genmab A/S ADR (GMAB) Stock Price, Quote & News

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 20 27 28

Website: www.genmab.com

Address:

Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

PetrCZE Sep. 11 at 11:57 AM

$GMAB What a ride last month!

0 · Reply

Pika_Capital Sep. 3 at 4:29 PM

$GMAB most likely you wont see $20 again here. Those bargain prices are gone but everything under $30 is a buy imo if you are patient to hold for few years.

2 · Reply

CDMO Sep. 3 at 1:46 PM

$GMAB looks like its finally recovering! I am still down 7% lol

2 · Reply

Thestocktraderhubzee Sep. 3 at 12:44 PM

$GMAB Genmab Announces Updated Results From Phase 2 EPCORE Trial Evaluating Epcoritamab, Showing Feasibility Of Treating And Monitoring Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1 · Reply

BigSqueezeComing Aug. 29 at 9:21 AM

$GMAB A 95% overall response rate (85% CRR) in frontline FL is far above what most oncology combos achieve. • Suggests epcoritamab could displace or complement chemotherapy in first-line settings — a massive market. load up

0 · Reply

BigSqueezeComing Aug. 29 at 9:19 AM

$GMAB Genmab A/S (GMAB)'s Epcoritamab Delivers 95% Response in Lymphoma By Laiba Immad | August 29, 2025, 5:12 AM

0 · Reply

CDMO Aug. 28 at 6:43 PM

$GMAB finally over 25 again

0 · Reply

txbondman Aug. 21 at 1:48 PM

sld some winners (partial) to take profits. sld $GMAB for a 15% gain;

0 · Reply

Pika_Capital Aug. 20 at 2:07 AM

$GMAB this is gonna be a safe haven when overvalued tech starts correcting

1 · Reply

savepig Aug. 15 at 2:33 PM

$GMAB If you dont like the look of this chart i have an anti depressant to sell you https://www.tradingview.com/x/G2oKAlWB/

0 · Reply

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Sep 12, 2025, 6:15 AM EDT - 2 days ago

Genmab: A Matter Of Time

Sep 9, 2025, 6:41 PM EDT - 4 days ago

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:57 PM EDT - 4 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Sep 9, 2025, 2:54 PM EDT - 4 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Sep 9, 2025, 2:39 PM EDT - 4 days ago

10 stocks to consider if you want alternatives to the expensive S&P 500

SPY AEG EFA NGG

$Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)$

Sep 3, 2025, 8:30 AM EDT - 10 days ago

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Aug 26, 2025, 9:31 AM EDT - 18 days ago

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 26, 2025, 8:00 AM EDT - 18 days ago

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

Aug 8, 2025, 1:23 PM EDT - 5 weeks ago

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

ABBV

Aug 7, 2025, 8:18 PM EDT - 5 weeks ago

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:08 AM EDT - 5 weeks ago

Genmab Announces Financial Results for the First Half of 2025

$Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)$

Aug 7, 2025, 10:31 AM EDT - 5 weeks ago

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

Aug 1, 2025, 8:31 AM EDT - 6 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Aug 1, 2025, 6:54 AM EDT - 6 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Jul 16, 2025, 6:29 AM EDT - 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Jul 1, 2025, 8:00 AM EDT - 2 months ago

Genmab Announces Changes to its Executive Committee

Jun 30, 2025, 9:30 AM EDT - 2 months ago

Completion of Share Buy-back Program

Jun 23, 2025, 9:18 AM EDT - 2 months ago

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Jun 23, 2025, 8:19 AM EDT - 2 months ago

Transactions in Connection with Share Buy-back Program

$Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)$

Jun 15, 2025, 5:00 AM EDT - 3 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Jun 12, 2025, 1:08 PM EDT - 3 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Jun 2, 2025, 2:30 PM EDT - 3 months ago

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

May 27, 2025, 9:55 AM EDT - 3 months ago

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

May 22, 2025, 5:05 PM EDT - 4 months ago

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

May 21, 2025, 10:02 AM EDT - 4 months ago

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

May 19, 2025, 7:03 AM EDT - 4 months ago

Genmab A/S: Transitioning From Royalty Model To Commercial-Stage Oncology

May 14, 2025, 10:15 AM EDT - 4 months ago

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

May 8, 2025, 11:01 AM EDT - 4 months ago

Genmab Announces Financial Results for the First Quarter of 2024

$Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)$

May 1, 2025, 8:24 PM EDT - 4 months ago

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Apr 15, 2025, 7:36 AM EDT - 5 months ago

Genmab's Outlook Beyond Darzalex's Patent Cliff

Apr 15, 2025, 6:22 AM EDT - 5 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Apr 10, 2025, 12:20 PM EDT - 5 months ago

Genmab A/S Share Capital Reduction

Apr 7, 2025, 7:43 AM EDT - 5 months ago

Transactions In Connection with Share Buy-back Program

Apr 1, 2025, 3:53 PM EDT - 5 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Mar 31, 2025, 11:20 AM EDT - 5 months ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Mar 31, 2025, 8:18 AM EDT - 5 months ago

Transactions in connection with share buy-back program

Mar 27, 2025, 2:27 PM EDT - 6 months ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Mar 27, 2025, 8:00 AM EDT - 6 months ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Mar 25, 2025, 5:28 PM EDT - 6 months ago

Genmab Announces Initiation of Share Buy-Back Program

Mar 21, 2025, 11:29 PM EDT - 6 months ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Mar 17, 2025, 12:19 PM EDT - 6 months ago

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Mar 14, 2025, 2:30 PM EDT - 6 months ago

Genmab: GEN3014's Demise And Implications For The HexaBody Platform

Mar 12, 2025, 2:13 PM EDT - 6 months ago

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Mar 12, 2025, 10:23 AM EDT - 6 months ago

Passing of Genmab A/S' Annual General Meeting

Mar 10, 2025, 10:21 AM EDT - 6 months ago

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Feb 28, 2025, 4:00 PM EST - 7 months ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

$EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma$

Feb 20, 2025, 8:00 AM EST - 7 months ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Feb 19, 2025, 9:14 AM EST - 7 months ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Feb 18, 2025, 2:25 AM EST - 7 months ago

Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon

JNJ

PetrCZE Sep. 11 at 11:57 AM

$GMAB What a ride last month!

0 · Reply

Pika_Capital Sep. 3 at 4:29 PM

$GMAB most likely you wont see $20 again here. Those bargain prices are gone but everything under $30 is a buy imo if you are patient to hold for few years.

2 · Reply

CDMO Sep. 3 at 1:46 PM

$GMAB looks like its finally recovering! I am still down 7% lol

2 · Reply

Thestocktraderhubzee Sep. 3 at 12:44 PM

$GMAB Genmab Announces Updated Results From Phase 2 EPCORE Trial Evaluating Epcoritamab, Showing Feasibility Of Treating And Monitoring Relapsed/Refractory Diffuse Large B-Cell Lymphoma

1 · Reply

BigSqueezeComing Aug. 29 at 9:21 AM

0 · Reply

BigSqueezeComing Aug. 29 at 9:19 AM

$GMAB Genmab A/S (GMAB)'s Epcoritamab Delivers 95% Response in Lymphoma By Laiba Immad | August 29, 2025, 5:12 AM

0 · Reply

CDMO Aug. 28 at 6:43 PM

$GMAB finally over 25 again

0 · Reply

txbondman Aug. 21 at 1:48 PM

sld some winners (partial) to take profits. sld $GMAB for a 15% gain;

0 · Reply

Pika_Capital Aug. 20 at 2:07 AM

$GMAB this is gonna be a safe haven when overvalued tech starts correcting

1 · Reply

savepig Aug. 15 at 2:33 PM

$GMAB If you dont like the look of this chart i have an anti depressant to sell you https://www.tradingview.com/x/G2oKAlWB/

0 · Reply

JarvisFlow Aug. 15 at 12:00 PM

HC Wainwright & Co. has adjusted their stance on Genmab ( $GMAB ), setting the rating to Buy with a target price of 35 → 36.

0 · Reply

satsandstocks Aug. 14 at 2:38 PM

$GMAB Monthly chart - patience needed

0 · Reply

PetrCZE Aug. 8 at 5:06 PM

$GMAB Added today. Very attractive valuation even by considering the risks.

1 · Reply

Biotekman Aug. 8 at 12:23 PM

$GMAB Current PER TTM is 10.5, don't be fooled by the multiples given by the common screeners: they are WRONG! GMAB has changed its reference currency this year, and it creates some bugs in financial websites. Use the EPS indicated in the last report of Genmab. What a bargain!

1 · Reply

SheriffGrover Aug. 8 at 11:55 AM

$GMAB https://www.investing.com/news/transcripts/earnings-call-transcript-genmab-q2-2025-earnings-beat-forecasts-stock-up-55-93CH-4178947

1 · Reply

Biotekman Aug. 8 at 10:42 AM

$GMAB Haha -5% for GMAB after good earnings, good clinical results, increase of the guidance and raise of the target price by the analysts 😂. TIME TO LOAD MORE!!!

0 · Reply

Biotekman Aug. 7 at 4:36 PM

$GMAB My dear Gem-mab, my sweet Gem-mab, I LOVE YOU!!!

0 · Reply

Pika_Capital Aug. 7 at 3:48 PM

$GMAB this thing is a monster. Keeps delivering quarter after quarter. Matter of time when are back to $40+

0 · Reply

SheriffGrover Aug. 7 at 3:37 PM

$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2025

2 · Reply

SheriffGrover Aug. 7 at 3:07 PM

$GMAB https://x.com/Genmab/status/1953466877218357376

0 · Reply

SheriffGrover Aug. 7 at 2:55 PM

$GMAB https://ir.genmab.com/news-releases/news-release-details/genmab-announces-phase-3-epcorer-fl-1-clinical-trial-met-dual

0 · Reply

Thestocktraderhubzee Aug. 7 at 2:33 PM

$GMAB Genmab Reports Results Of Phase 3 EPCORE FL-1 Trial Evaluating Subcutaneous Epcoritamab In Combination With Rituximab And Lenalidomide Versus R2 Alone For Treatment Of Adult Patients With R/R FL

0 · Reply

Market Cap	17.85B
Revenue (ttm)	3.12B
Net Income (ttm)	1.14B
EPS (ttm)	N/A
PE Ratio	16.73
Forward PE	16.97
Profit Margin	36.44%
Debt to Equity Ratio	0.00

Volume	1,484,400
Avg Vol	1,264,592
Day's Range	N/A - N/A
Shares Out	641.59M
Stochastic %K	71%
Beta	0.93
Analysts	Sell
Price Target	$30.90